<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04216121</url>
  </required_header>
  <id_info>
    <org_study_id>S63270</org_study_id>
    <nct_id>NCT04216121</nct_id>
  </id_info>
  <brief_title>LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib</brief_title>
  <acronym>LAT-FLOSI</acronym>
  <official_title>Local AblativeTherapy for Oligoprogressive Non-Small-Cell Lung Cancer Treated With First-line OSImertinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine whether in patients with EGFR mutated advanced NSCLC and osimertinib as&#xD;
      first-line treatment, the (repeated) use of LAT to ≤ 3 OP lesions and continuation of&#xD;
      first-line osimertinib, improves the median progression-free survival by more than 3 months&#xD;
      (i.e. PFS2-PFS1 = &gt;3 months).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The (repeated) use of LAT to ≤ 3 OP lesions with continuation of first-line osimertinib, is&#xD;
      endorsed by international guidelines (NCCN, ESMO).&#xD;
&#xD;
      In this phase IIb prospective non-randomized observational trial, we want to document the&#xD;
      benefit of LAT in this patient cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 10, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>PFS 2</measure>
    <time_frame>Time from start of osimertinib until first PD after LAT or death whichever comes first, up to 3 year after LAT</time_frame>
    <description>Progression Free Survival 2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to next line systemic therapy</measure>
    <time_frame>Time from LAT until initiation of next line systemic therapy or death whichever comes first, up to 3 years after LAT</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patterns of disease progression</measure>
    <time_frame>Time from LAT until disease progression or death whichever comes first, up to 3 years after LAT</time_frame>
    <description>Patterns of disease progression after local ablative therapy (LAT) identified on sequential CT scans taken at 3 monthly intervals to document the natual history of the disease after LAT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy induced toxicity</measure>
    <time_frame>Change in toxicity measured from baseline up to 3 years after radiotherapy</time_frame>
    <description>Acute and late radiotherapy induced toxicities assessed using the CTCAE v4.0. and the RTOG/EORTC late morbidity score. Acute events are defined as ≤ 90 days post SBRT and late events &gt; 90 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Change in quality of life measured from baseline up to 3 years after radiotherapy</time_frame>
    <description>Quality of life is measured by the EORTC QLQ-LC13 questionnaire comprised both of multi-item and single-item measures of lung cancer-associated symptoms (i.e. coughing, haemoptysis, dyspnoea and pain) and side-effects from conventional chemo- and radiotherapy (i.e. hair loss, neuropathy, sore mouth and dysphagia).</description>
  </secondary_outcome>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Local ablative therapy</intervention_name>
    <description>Stereotactic body radiotherapy</description>
    <other_name>SBRT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local ablative therapy</intervention_name>
    <description>Surgery</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Established histological diagnosis of advanced NSCLC, not suitable for radical treatment,&#xD;
        with an EGFR actionable mutation receiving first-line targeted TKI therapy with&#xD;
        osimertinib. Confirmed oligoprogressive disease defined as ≤ 3 intra- and extracranial&#xD;
        sites of progressive disease&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female, ≥ 18 years of age&#xD;
&#xD;
          2. Established histological diagnosis of advanced NSCLC, not suitable for radical&#xD;
             treatment, with an EGFR actionable mutation receiving first-line targeted TKI therapy&#xD;
             with osimertinib&#xD;
&#xD;
          3. Initial radiologically confirmed response (at least stable disease) to osimertinib&#xD;
             assessed 3 months post commencing osimertinib according to RECIST criteria v1.1.&#xD;
&#xD;
          4. Confirmed OPD defined as ≤ 3 intra- and extracranial sites of progressive disease. OP&#xD;
             may be defined as progression of an individual metastasis according to RECIST or on 2&#xD;
             consecutive imaging studies at least 2 months apart with a minimum of 5mm increase in&#xD;
             size from baseline or an unambiguous development of a new metastatic lesion with a&#xD;
             grand total of 3 lesions. All sites must be visible, imaging defined targets, not&#xD;
             previously treated with radiation or radiofrequency and suitable for treatment with&#xD;
             LAT as determined by the local multi-disciplinary team (MDT).&#xD;
&#xD;
          5. Adequate baseline organ function to allow LAT to all the OP targets.&#xD;
&#xD;
          6. Predicted life expectancy ≥ 6 months&#xD;
&#xD;
          7. Karnofsky Index ≥ 60% and ECOG 0-2&#xD;
&#xD;
          8. Provision of written informed consent&#xD;
&#xD;
          9. Female participants must be surgically sterile or postmenopausal if SBRT is planned to&#xD;
             the abdominal area or must agree to use effective contraception during the period of&#xD;
             therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. &gt; 3 sites of progressive disease&#xD;
&#xD;
          2. Oligoprogressive metastases not amenable to LAT&#xD;
&#xD;
          3. Radiotherapy or radiofrequency ablation near the OP lesion prior to the inclusion in&#xD;
             the LAT-FLOSI study&#xD;
&#xD;
          4. Co-morbidities considered clinically precluding the safe use of LAT&#xD;
&#xD;
          5. Any psychological, sociological or geographical issue potentially hampering compliance&#xD;
             with the study&#xD;
&#xD;
          6. Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patrick Berkovic, MD</last_name>
    <phone>+32-16-34-51-15</phone>
    <email>Patrick.berkovic@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Els Wauters, MD, PhD</last_name>
    <phone>+32 16-34-09-42</phone>
    <email>els.wauters@uzleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Berkovic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Els Wauters, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Johan Vansteenkiste, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maarten Lambrecht, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christel Oyen, RN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 9, 2019</study_first_submitted>
  <study_first_submitted_qc>December 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 2, 2020</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First line osimertinib</keyword>
  <keyword>Local ablative therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

